background
excess
monocytemacrophag
activ
develop
cytokin
storm
subsequ
acut
lung
injuri
lead
acut
respiratori
distress
syndrom
ard
fear
consequ
infect
abil
recogn
potenti
interven
earli
patient
greatest
risk
develop
complic
could
great
clinic
util
method
perform
detail
flow
cytometr
analysi
peripher
blood
sampl
sever
acut
respiratori
syndrom
coronaviru
also
known
corona
viru
new
coronaviru
first
identifi
wuhan
china
decemb
frequent
induc
fatal
inflammatori
respons
acut
lung
injuri
march
total
confirm
case
report
worldwid
estim
mortal
http
coronavirusjhuedumaphtml
patient
experi
spectrum
diseas
mild
ill
vari
sever
pneumonia
way
ard
sepsi
multiorgan
failur
death
initi
clinic
featur
diseas
onset
fever
dri
cough
myalgia
fatigu
dyspnea
major
patient
develop
pneumonia
proceed
case
respiratori
failur
requir
intub
ventilatori
support
patient
go
develop
pneumonia
dyspnea
develop
median
day
onset
ill
radiograph
abnorm
ct
chest
xray
consist
groundglass
opac
focal
consolid
seen
patient
pneumonia
major
caus
death
includ
respiratori
failur
myocardi
damag
due
myocard
acut
kidney
injuri
secondari
infect
coagulopathi
seen
approxim
nonsurvivor
mortal
increas
age
patient
underli
comorbid
hypertens
diabet
mellitu
coronari
heart
diseas
chronic
lung
diseas
cancer
accord
recent
retrospect
report
wuhan
clinic
predictor
increas
mortal
multivari
analysi
includ
advanc
age
progress
organ
failur
elev
ddimer
admiss
factor
significantli
associ
poor
outcom
univari
analysi
includ
elev
level
serum
ferritin
alanin
amino
transferas
alt
lactat
dehydrogenas
ldh
highli
sensit
cardiac
troponin
well
reduc
level
lymphocyt
hemoglobin
hb
platelet
serum
albumin
best
recogn
hematolog
abnorm
lymphopenia
seen
sever
case
sever
lymphopenia
link
outcom
sinc
regulatori
cell
play
import
role
dampen
immun
respons
excess
elimin
cell
could
result
uncheck
innat
immun
respons
lead
uncontrol
inflammatori
respons
inde
grow
evid
implic
excess
monocytemacrophag
activ
associ
cytokin
storm
pathophysiolog
sever
diseas
relat
complic
despit
report
date
relat
abnorm
monocyt
patient
herein
describ
novel
observ
relat
chang
monocyt
morpholog
activ
statu
correl
prognosi
sever
infect
readili
quantifi
flow
cytometri
concurr
measur
forward
scatter
fsc
ssc
measur
cell
size
complex
respect
specif
identifi
presenc
popul
monocyt
higher
fsc
normal
fschigh
typic
seen
type
viral
infect
analysi
reveal
fschigh
monocyt
express
well
along
marker
associ
polar
secret
tnfalpha
studi
case
xian
hospit
shaanxi
provinci
infecti
diseas
hospit
first
affili
hospit
xian
jiaotong
univers
design
hospit
local
govern
shaanxi
provinc
china
patient
diagnos
accord
world
health
organ
interim
guidanc
http
wwwwhointpublicationsdetailinfectionpreventionandcontrolduringhealthcarewhenno
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
blood
sampl
patient
collect
laboratori
assess
accord
doctor
instruct
patient
receiv
treatment
blood
sampl
full
list
antibodi
use
studi
includ
supplementari
file
peripher
blood
smear
made
stain
wright
stain
use
sysmex
kobe
japan
autom
smearmakerstain
system
examin
stain
blood
smear
semiautom
digit
cell
morpholog
system
cellavis
cellavis
ab
lund
sweden
follow
manufactur
instruct
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
investig
potenti
effect
fsclow
monocyt
fsclowfschigh
monocyt
discharg
patient
hospit
perform
kaplanmei
surviv
analysi
patient
categor
high
fsclow
monocyt
low
fsclow
monocyt
group
base
median
fsclow
monocyt
valu
surviv
curv
obtain
group
logrank
test
implement
examin
statist
signific
differ
surviv
curv
two
group
similar
analysi
also
conduct
fsclowfschigh
monocyt
addit
cox
model
also
fit
adjust
potenti
effect
age
gender
statist
valu
present
mean
sd
data
analyz
use
graphpad
prism
version
graphpad
softwar
san
diego
ca
usa
statist
signific
calcul
student
unpair
ttest
differ
p
consid
statist
signific
better
understand
impact
immun
respons
origin
sought
investig
chang
immun
cell
peripher
blood
patient
use
flow
cytometri
unexpectedli
test
patient
found
presenc
specif
popul
right
next
popul
monocyt
fschigh
use
fsc
ssc
paramet
figur
contrast
popul
virtual
absent
healthi
donor
figur
c
valid
natur
fschigh
popul
perform
wrightgiemsa
stain
blood
smear
shown
figur
confirm
presenc
increas
number
larger
atyp
vacuol
monocyt
normal
seen
peripher
blood
healthi
individu
tabl
show
total
number
monocytesmacrophag
peripher
differ
patient
healthi
donor
increas
proport
activ
monocytesmacrophag
patient
next
analyz
express
phenotyp
marker
fschigh
popul
use
flow
cytometri
shown
figur
b
cell
strongli
posit
suggest
belong
monocyt
lineag
importantli
macrophag
marker
express
popul
sinc
consid
marker
typic
polar
consid
typic
polar
suggest
fschigh
popul
contain
macrophag
confirm
suspicion
perform
intracellular
stain
valid
express
cytokin
fschigh
cell
shown
figur
cytokin
found
secret
hand
cytokin
also
express
cell
fschigh
popul
collect
find
strongli
support
fschigh
popul
compos
macrophag
mix
polar
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
nonclass
monocyt
increas
suggest
monocyt
patient
differ
healthi
donor
shown
entri
receptor
sarscov
specul
direct
viral
infect
could
trigger
observ
chang
monocyt
investig
whether
monocyt
express
therefor
could
infect
perform
flow
cytometri
stain
human
monocyt
cell
line
well
murin
macrophag
cell
line
demonstr
monocytemacrophag
cell
posit
figur
moreov
confirm
monocyt
peripher
blood
healthi
donor
patient
posit
figur
importantli
found
express
level
monocytesmacrophag
patient
significantli
lower
healthi
donor
figur
signific
differ
time
discharg
hospit
identifi
patient
low
high
level
fsclow
monocyt
figur
fsclowfschigh
monocyt
figur
differ
still
signific
adjust
age
gender
cox
model
fsclow
monocyt
fsclowfschigh
monocyt
p
patient
includ
studi
three
admit
icu
focus
total
number
monocyt
percentag
fsclow
fschigh
observ
obviou
differ
nonicu
patient
shown
figur
three
patient
lower
number
monocyt
significantli
higher
percentag
fschigh
fsclow
popul
moreov
length
hospit
three
icu
patient
day
significantli
longer
averag
day
nonicu
patient
confirm
fschigh
popul
specif
marker
infect
investig
whether
fschigh
popul
infecti
diseas
shown
figur
case
hiv
case
hiv
concurr
tb
tuberculosi
case
influenza
viru
subtyp
case
hantaan
orthohantaviru
htnv
case
malaria
evid
smiliar
fschigh
popul
viral
nonvir
infect
report
find
patient
confirm
infect
vari
degre
sever
identifi
distinct
chang
morpholog
function
monocytesmacrophag
predict
sever
diseas
likelihood
icu
admiss
length
hospit
stay
full
recoveri
monocyt
character
shift
forward
scatter
flow
cytometri
well
rel
increas
intermedi
nonclass
monocyt
fschigh
monocyt
express
macrophag
marker
repres
inflammatori
monocyt
subset
typic
seen
healthi
control
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
respons
monocytemacrophag
neutrophil
accumul
highlight
sarscov
merscov
encod
multipl
protein
antagon
ifn
respons
earli
antagon
ifn
respons
might
delay
evad
innat
immun
respons
conclud
delay
ifn
signal
could
orchestr
inflammatori
monocytemacrophag
respons
sensit
cell
apoptosi
result
dysregul
inflammatori
respons
inflammatori
macrophag
accumul
lung
like
sourc
proinflammatori
cytokin
chemokin
associ
fatal
diseas
induc
human
coronaviru
infect
sar
autopsi
find
patient
mirror
find
interestingli
confirm
monocyt
infect
patient
posit
sinc
receptor
use
gain
entri
cell
suggest
possibl
monocyt
patient
may
directli
infect
lead
abort
replic
delay
type
ifn
respons
cell
inde
sarscov
viru
found
infect
monocyt
though
replic
poor
infect
monocyt
sarscov
associ
inflammatori
activ
alter
immun
functionrel
gene
express
inflammatori
cytokin
gmcsf
also
stimul
differenti
monocyt
macrophag
found
treatment
high
dose
capabl
induc
macrophag
differenti
normal
peripher
blood
sampl
within
day
wherea
gmcsf
plu
requir
day
data
shown
similar
find
zhou
colleagu
recent
report
presenc
significantli
higher
percentag
inflammatori
monocyt
peripher
blood
patient
compar
normal
healthi
control
also
report
percentag
monocyt
much
higher
sever
pulmonari
syndrom
patient
icu
also
show
monocyt
capabl
secret
gmcsf
similar
find
could
also
secret
higher
icu
patient
associ
cytokin
storm
describ
model
wherebi
abnorm
respons
trigger
gmcsf
induc
monocytemacrophag
activ
lead
increas
produc
monocyt
migrat
lung
induc
subsequ
lung
damag
along
inflammatori
cytokin
storm
also
support
recent
data
relat
singl
cell
rna
sequenc
immun
cell
bronchoalveolar
lavag
sampl
patient
provid
import
insight
immun
microenviron
infect
lung
data
show
ficolin
express
monocytederiv
macrophag
supplant
fatti
acid
bind
express
alveolar
macrophag
predomin
macrophag
subset
lung
patient
ard
cell
highli
inflammatori
enorm
chemokin
produc
implic
cytokin
storm
base
data
pilot
trial
tociluzumab
receptor
antibodi
approv
treatment
rheumatoid
arthriti
well
cart
associ
cytokin
releas
syndrom
recent
conduct
small
number
sever
patient
promis
result
treatment
cytokin
storm
receptor
antagonist
anakinra
janu
kinas
jak
inhibitor
may
also
prove
use
though
date
littl
clinic
experi
agent
treat
given
central
role
monocyt
appear
play
infect
import
recognis
limit
inform
provid
routin
autom
blood
analyz
inde
contribut
monocyt
patient
patholog
may
overlook
patient
sever
diseas
monocytopen
may
well
reflect
migrat
inflammatori
monocytemacrophag
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
lung
affect
organ
morpholog
examin
peripher
blood
film
reveal
somewhat
larger
atyp
vacuol
monocyt
find
specif
shown
simpl
assess
fsc
flow
cytometri
context
infect
rapidli
identifi
patient
increas
proport
larg
activ
tnf
secret
monocyt
sever
diseas
greatest
risk
icu
admiss
contrast
patient
high
proport
normal
monocyt
better
prognosi
earlier
recoveri
discharg
hospit
find
appear
rel
specif
seen
similar
pattern
patient
viral
ill
influenza
hiv
hantaanviru
conclus
patient
sever
infect
monocyt
activ
associ
inflammatori
respons
associ
characterist
chang
rapidli
identifi
simpl
bloodbas
flow
cytometrybas
assay
serial
monitor
acknowledg
limit
studi
given
small
sampl
size
feel
nevertheless
find
could
great
help
guid
prognost
treatment
patient
merit
evalu
confirm
futur
studi
fund
studi
support
special
fund
xian
jiaotong
univers
health
scienc
center
key
project
scienc
technolog
shaanxi
grant
data
use
support
find
studi
avail
correspond
author
upon
request
right
reserv
reus
allow
without
permiss
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
peerreview
http
doi
medrxiv
preprint
